Abstract

 The results of 1 randomized controlled trial did not find a difference in functional status (6-minute walk distance and New York Heart Association class), hand grip strength, or health-related quality of life for patients who underwent a transcatheter aortic valve implantation treated with iron isomaltoside versus placebo.
 There was 1 (1.4%) hypersensitivity reaction and 1 (1.4%) episode of chest pain in patients treated with iron isomaltoside in the randomized controlled trial. Rates of other adverse events were similar between patients treated with iron isomaltoside and placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have